CD8A and neoplasm: The above results indicate that NKP-1339/miR-142-NBs combined with US treatment can considerably promote CD8+ T cell proliferation and cytotoxicity, enhance the secretion of immune-related molecules such as TNF-α and IFN-γ, and further strengthen the tumor immune response.